AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19008470 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble RANKL in vitro
Number of subjects: 0
Study 16182104 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular red wine (250 mL)
Number of subjects: 15
Study 16182104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dealcoholized red wine (250 mL)
Number of subjects: 15
Study 16182104 — intervention group
Group type: COMPARATOR
Intervention: Control (no red wine)
Number of subjects: 15
Study 12675998 — intervention group
Group type: EXPERIMENTAL
Intervention: FbM (filled by mass)
Number of subjects: 131
Study 12675998 — intervention group
Group type: COMPARATOR
Intervention: FbIU (filled by IU)
Number of subjects: 131
Study 10674881 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 0
Study 10674881 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 0
Study 10674881 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg and Megestrol acetate
Number of subjects: 0
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata ≤55 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata 56 to 65 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata 66 to 75 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Congestive heart failure in age strata >75 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata ≤55 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata 56 to 65 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata 66 to 75 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing wall motion index in age strata >75 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata ≤55 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata 56 to 65 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata 66 to 75 years
Number of subjects: 6676
Study 8712136 — intervention group
Group type: EXPERIMENTAL
Intervention: LV systolic dysfunction in age strata >75 years
Number of subjects: 6676
Study 1987807 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (10 micrograms/kg iv)
Number of subjects: 10
Study 1987807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6345893 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzer clearance of urea (Kd, ml/min)
Number of subjects: 0
Study 6345893 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of dialysis (Td, hr or min)
Number of subjects: 0
Study 6345893 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake monitoring (PCR, g/day)
Number of subjects: 0
Study 31932699 — intervention group
Group type: COMPARATOR
Intervention: Attention Control (AC) group (physical activity recommendations)
Number of subjects: 249
Study 31932699 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume of moderate-intensity continuous training
Number of subjects: 249
Study 31932699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume and high-intensity interval training (HIIT)
Number of subjects: 249
Study 31932699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume-HIIT
Number of subjects: 249
Study 31185374 — intervention group
Group type: EXPERIMENTAL
Intervention: Online TMS to the left superior parietal lobe
Number of subjects: 0
Study 31185374 — intervention group
Group type: COMPARATOR
Intervention: Active vertex stimulation (control)
Number of subjects: 0
Study 27668943 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose (FD) anticonvulsants
Number of subjects: 36
Study 27668943 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose (HD) anticonvulsants
Number of subjects: 36
Study 27668943 — intervention group
Group type: COMPARATOR
Intervention: Stop anticonvulsants
Number of subjects: 36
Study 27098525 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Degludec (IDeg)
Number of subjects: 833
Study 27098525 — intervention group
Group type: COMPARATOR
Intervention: Insulin Glargine (IGlar)
Number of subjects: 833
Study 23346907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide indirect pulp treatment (CH‐IPT)
Number of subjects: 50
Study 23346907 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic sterilization using a mixture of three antibiotics (3Mix‐MP)
Number of subjects: 50
Study 23938229 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation plus optimal drug therapy
Number of subjects: 30
Study 23938229 — intervention group
Group type: COMPARATOR
Intervention: Optimal drug therapy
Number of subjects: 30
Study 18775043 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous diagnostic coved-type ECGs (group A)
Number of subjects: 89
Study 18775043 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous non-diagnostic ECGs (group A)
Number of subjects: 89
Study 18775043 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug challenge ECGs (group B)
Number of subjects: 89
Study 18165484 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Tests (RDTs)
Number of subjects: 0
Study 18165484 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 0
Study 15767153 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof MA60BM (Alcon)
Number of subjects: 63
Study 15767153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensar AR40 (AMO)
Number of subjects: 63
Study 15767153 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal ACR6D (Corneal Laboratoire)
Number of subjects: 63
Study 15767153 — intervention group
Group type: COMPARATOR
Intervention: Normal phakic eyes (control group)
Number of subjects: 63
Study 12067328 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (6 MIU once weekly i.m.)
Number of subjects: 20
Study 12067328 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 9498655 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 4mg day(-1) (H)
Number of subjects: 29
Study 9498655 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 0.5 mg day(-1) (L)
Number of subjects: 29
Study 9498655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 29
Study 8530333 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine 150 mg/day
Number of subjects: 57
Study 8530333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 2226384 — intervention group
Group type: EXPERIMENTAL
Intervention: Loud voice commands
Number of subjects: 40
Study 2226384 — intervention group
Group type: COMPARATOR
Intervention: Normal voice commands
Number of subjects: 40
Study 31847 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy and imipramine hydrochloride
Number of subjects: 111
Study 31847 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy and placebo
Number of subjects: 111
Study 31847 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy and imipramine
Number of subjects: 111
Study 31847 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 111
Study 31847 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 111
Study 31847 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens (including imipramine and placebo) in simple phobic patients
Number of subjects: 111
Study 31847 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after one year
Number of subjects: 111
Study 31847 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 111
Study 31484021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign® occupational therapy (LR-OT)
Number of subjects: 73
Study 31484021 — intervention group
Group type: COMPARATOR
Intervention: No-contact comparison group
Number of subjects: 73
Study 29075347 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual circumference measurement by 6 observers
Number of subjects: 58
Study 29075347 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second measurements by all observers
Number of subjects: 58
Study 26113171 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity (TPA)
Number of subjects: 141
Study 26113171 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self‐management Programme (CPSMP)
Number of subjects: 141
Study 26113171 — intervention group
Group type: COMPARATOR
Intervention: Reference group (REF)
Number of subjects: 141
Study 23898894 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal treatment group received one unit of packed red blood cells and as much blood as needed to maintain hemoglobin concentrations at greater than 10 g/dL; median two units of blood received.
Number of subjects: 139
Study 23898894 — intervention group
Group type: COMPARATOR
Intervention: Restrictive treatment group received transfusions if they developed symptoms of anemia or their hemoglobin fell below 8 g/dL; median zero units of blood received.
Number of subjects: 139
Study 21704240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg in fed state
Number of subjects: 73
Study 21704240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after light morning meal
Number of subjects: 73
Study 21704240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after light evening meal
Number of subjects: 73
Study 21704240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after standard evening meal
Number of subjects: 73
Study 21704240 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg after high-fat evening meal
Number of subjects: 73
Study 18996650 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal repair of cystocele with mesh
Number of subjects: 6
Study 18996650 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal repair of cystocele without mesh
Number of subjects: 6
Study 18996650 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal repair of rectocele with mesh
Number of subjects: 6
Study 18996650 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal repair of apical prolapse with mesh
Number of subjects: 6
Study 18996650 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal repair of POP with mesh
Number of subjects: 6
Study 18996650 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal repair of POP without mesh
Number of subjects: 6
Study 16319918 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg/day for 2 weeks, then 20 mg/day for 2 weeks, then 30 mg/day for 2 weeks
Number of subjects: 62
Study 16319918 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (various doses)
Number of subjects: 62
Study 12177026 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief negotiation
Number of subjects: 1658
Study 12177026 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct advice
Number of subjects: 1658
Study 12177026 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control
Number of subjects: 1658
Study 10459684 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg of triazolam (TRZ)
Number of subjects: 10
Study 10459684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7608255 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin administration (850 mg, twice daily for 4 months)
Number of subjects: 24
Study 7608255 — intervention group
Group type: COMPARATOR
Intervention: Low calorie diet (1500 Cal/day)
Number of subjects: 24
Study 2404483 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 2404483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 358763 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (BFT), 10 mg, given orally after fasting overnight
Number of subjects: 8
Study 358763 — intervention group
Group type: COMPARATOR
Intervention: Bendroflumethiazide (BFT), 10 mg, given orally together with a meal
Number of subjects: 8
Study 29634987 — intervention group
Group type: EXPERIMENTAL
Intervention: Category average reference point (CARP) provided by a credible source
Number of subjects: 698
Study 29634987 — intervention group
Group type: COMPARATOR
Intervention: Category average reference point (CARP)
Number of subjects: 698
Study 25125244 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (iNPWT)
Number of subjects: 21
Study 25125244 — intervention group
Group type: COMPARATOR
Intervention: Standard wound dressing
Number of subjects: 21
Study 25323335 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymizer
Number of subjects: 43
Study 25323335 — intervention group
Group type: COMPARATOR
Intervention: CNC
Number of subjects: 43
Study 23085128 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 ICD shocks during DFT testing
Number of subjects: 1659
Study 23085128 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ICD shock during DFT testing
Number of subjects: 1659
Study 23085128 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ICD shocks during DFT testing
Number of subjects: 1659
Study 23085128 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 or more ICD shocks during DFT testing
Number of subjects: 1659
Study 23085128 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy ICD shocks (>20 J)
Number of subjects: 1659
Study 23085128 — intervention group
Group type: COMPARATOR
Intervention: Low-energy ICD shocks (≤20 J)
Number of subjects: 1659
Study 20586675 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote programming
Number of subjects: 70
Study 20586675 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face programming
Number of subjects: 70
Study 18802184 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard drug counseling
Number of subjects: 130
Study 18802184 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing/skills-building therapy
Number of subjects: 130
Study 18802184 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for attending sessions and submitting marijuana-free urine specimens
Number of subjects: 130
Study 18802184 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiz scores
Number of subjects: 130
Study 18802184 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study 16007412 — intervention group
Group type: EXPERIMENTAL
Intervention: S21403 (mitiglinide) 40 mg
Number of subjects: 40
Study 16007412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12407036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed multiple dose antagonist protocol starting on day 6 of stimulation (group 1)
Number of subjects: 60
Study 12407036 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized protocol with the time of antagonist start according to follicle size (14 mm, group 2)
Number of subjects: 60
Study 12407036 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized single dose protocol (group 3)
Number of subjects: 60
Study 9802369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg twice daily)
Number of subjects: 46
Study 9802369 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 46
Study 7618619 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (150 mg/day in 3 separate doses)
Number of subjects: 15
Study 7618619 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day)
Number of subjects: 15
Study 7618619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2794181 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized nicotine fading and stop‐smoking contest
Number of subjects: 58
Study 2794181 — intervention group
Group type: COMPARATOR
Intervention: Contest‐only group
Number of subjects: 58
Study 414272 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol state (1.0 ml/kg)
Number of subjects: 28
Study 414272 — intervention group
Group type: COMPARATOR
Intervention: Sober state
Number of subjects: 28
Study 31601250 — intervention group
Group type: EXPERIMENTAL
Intervention: Social group intervention (sensitization/education of social groups about MRDT)
Number of subjects: 0
Study 31601250 — intervention group
Group type: EXPERIMENTAL
Intervention: Social group/provider intervention (social group treatment plus training of healthcare providers in health communication about MRDT)
Number of subjects: 0
Study 31601250 — intervention group
Group type: COMPARATOR
Intervention: Control (usual practice of provision of MRDT services by public primary healthcare providers and patent medicine vendors)
Number of subjects: 0
Study 28657701 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized SnF2 dentifrice
Number of subjects: 40
Study 25491347 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg zinc as zinc sulfate daily for 17 days
Number of subjects: 40
Study 25491347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23663094 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice (1140 mg/day)
Number of subjects: 60
Study 23663094 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT) - conjugated estrogen 0.312 mg/day and Medroxyprogesterone 2.5 mg/day
Number of subjects: 60
Study 23663094 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 60
Study 22898579 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox Kinect™ in multiplayer mode
Number of subjects: 14
Study 22898579 — intervention group
Group type: COMPARATOR
Intervention: Xbox Kinect™
Number of subjects: 14
Study 22898579 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii™ in multiplayer mode
Number of subjects: 14
Study 22898579 — intervention group
Group type: COMPARATOR
Intervention: Wii™
Number of subjects: 14
Study 19192469 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 314
Study 19192469 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 314
Study 19192469 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (white subjects)
Number of subjects: 314
Study 19192469 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (black/Hispanic subjects)
Number of subjects: 314
Study 17918451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bie Jia Jian
Number of subjects: 98
Study 17918451 — intervention group
Group type: COMPARATOR
Intervention: Western medicine for liver protection
Number of subjects: 98
Study 15121738 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (80% helium, 20% oxygen)
Number of subjects: 9
Study 15121738 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-path trumpet model considering axial diffusion
Number of subjects: 9
Study 11590989 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated olive oil
Number of subjects: 14
Study 11590989 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated safflower oil
Number of subjects: 14
Study 11590989 — intervention group
Group type: COMPARATOR
Intervention: Control (fasting state)
Number of subjects: 14
Study 9677769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (59 procedures by an experienced surgeon)
Number of subjects: 106
Study 9677769 — intervention group
Group type: COMPARATOR
Intervention: Group B (47 procedures by residents with less than ten cases experience)
Number of subjects: 106
Study 9677769 — intervention group
Group type: COMPARATOR
Intervention: Group C (20 procedures by residents with at least 5 tension-free repairs experience)
Number of subjects: 106
Study 9677769 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 106
Study 7928829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin modified release (MR) 100 mg bd
Number of subjects: 538
Study 7928829 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole 960 mg bd
Number of subjects: 538
Study 7928829 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim 200 mg bd
Number of subjects: 538
Study 7928829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin MR
Number of subjects: 538
Study 7928829 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 538
Study 7928829 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim
Number of subjects: 538
Study 29937267 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg or 100 mg daily)
Number of subjects: 10142
Study 29937267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study 27668546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx (Xtampza ER) administered sprinkled onto soft foods or via enteral feeding tubes
Number of subjects: 0
Study 27668546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone DETERx (Xtampza ER)
Number of subjects: 0
Study 25144697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survival skills training for 6 weeks
Number of subjects: 71
Study 25144697 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study 23746376 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR ≤29 mL/min/1.73 m²
Number of subjects: 5805
Study 23746376 — intervention group
Group type: COMPARATOR
Intervention: eGFR categories (75‐89, 60‐74, 45‐59, 30‐44)
Number of subjects: 5805
Study 23746376 — intervention group
Group type: COMPARATOR
Intervention: eGFR ≥90 mL/min/1.73 m²
Number of subjects: 5805
Study 20186426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 24
Study 20186426 — intervention group
Group type: COMPARATOR
Intervention: Stretching program
Number of subjects: 24
Study 19690125 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 205
Study 19690125 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 205
Study 16970531 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture for 30 seconds
Number of subjects: 18